Identification of breast cancer patients with a high risk of developing brain metastases: a single-institutional retrospective analysis

Table 1 Univariate analysis (Kaplan-Meier method) of possible factors associated with the development of brain metastasis of non-metastatic breast cancer patients at diagnosis

Characteristics		n	%	3-year brain metastasis-free survival	-95% CI	+95% CI	p-value*
Age (years)							0.10
	≤35	36	10.3	0.87	0.74	1.00
	>35	316	89.7	0.95	0.92	0.99
Menopausal status							0.33
	Pre-menopausal	165	47.0	0.95	0.91	0.99
	Post-menopausal	187	53.0	0.94	0.88	0.99
Body Mass Index							0.88
	<25	60	17.1	0.95	0.88	1.00
	25-29	118	33.6	0.96	0.91	1.00
	≥30	174	49.3	0.93	0.88	0.99
T stage							0.19
	0-2	200	56.7	0.96	0.92	1.00
	3-4	152	43.3	0.93	0.87	0.99
N stage							0.19
	0-1	253	72.1	0.95	0.91	0.99
	2-3	99	27.9	0.93	0.88	0.99
Stage							0.10
	Localized	133	37.9	0.95	0.89	1.00
	Regional	219	62.1	0.94	0.90	0.98
ER status							<0.001
	Positive	243	69.2	0.99	0.98	1.00
	Negative	109	30.8	0.84	0.74	0.94
PR status							0.01
	Positive	216	61.5	0.99	0.96	1.00
	Negative	136	38.5	0.88	0.80	0.95
HER2 status							0.31
	Positive	88	25.1	0.98	0.95	1.00
	Negative	264	74.9	0.93	0.89	0.98
Tumor subtype							<0.001
	Triple negative	63	17.7	0.78	0.64	0.93
	Her2 overexpressing	35	10.0	0.96	0.88	1.00
	Luminal A	201	57.3	0.98	0.95	1.00
	Luminal B	53	15.1	1.00	1.00	1.00

Abbreviation: 95% CI = 95% confidence interval of the 3-year brain metastasis-free survival; * = log rank test.

ISSN: 1471-2407